Long term treament of schizophrenia with risperidone : an international, ultcenter, open label trial. ris-int-36

Abstract EN

This is the Jordan part of an international, multicenter, open label study, which was designed to investigate the efficacy and safety of risperidone in the treatment of schizophrenia in the long term.

Fifty-eight patients with acute exacerbation of chronic schizophrenia were included in the study.

Fifteen were dropped out during the study for various reasons.

Statistically significant improvement in psychopathology was shown in all patients who completed the study.

The mean PANSS score at selection was 104.2 and was reduced to "49.2" at end point.

The mean percentage of improvement after 7 months was 52.4%.

Changes in CGI were consistent with these improvements, confirming that the changes were clinically meaningful.

Extrapyramidal side effects reached 6.8% but other adverse effects were very minimal